U.S., May 17 -- ClinicalTrials.gov registry received information related to the study (NCT06976216) titled 'A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease' on May 09.
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
Study Start Date: July 25
Study Type: INTERVENTIONAL
Condition:
Alzheimer's Disease
Intervention:
DRUG: KarXT
Specified dose on specified days
DRUG: KarX-EC
Specified dose on specified days
OTHER: Placebo
Specified dose on specified days
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Bristol-Myers Squibb
Published by HT Digital Content Services with perm...